Overview
Cyprumed is an Austria-based drug delivery company specializing in proprietary platforms for non-invasive oral administration of biologics, peptides like GLP-1 agonists, and BCS Class IV drugs. Their technology offers superior bioavailability, IP protection, scalable tablet formulations, and has demonstrated up to 70% relative oral bioavailability in preclinical studies. Recent partnerships, including a non-exclusive license with MSD (Merck & Co.) for oral peptide therapeutics, highlight their platform's potential.
Frequently asked questions
- What drug delivery technologies does Cyprumed offer?
- Cyprumed provides proprietary oral delivery platforms for peptides such as GLP-1 agonists and BCS Class IV drugs, featuring superior bioavailability, IP protection, scalable tablet formulations, and up to 70% relative oral bioavailability in preclinical rodent, dog, and non-human primate studies.
- What are Cyprumed's regulatory and IP capabilities?
- Cyprumed's technology uses GRAS-listed compounds, offers IP protection and freedom-to-operate, and holds patents like US10905744B2 for oral peptide formulations. They have licensed their platform non-exclusively to MSD with options for exclusivity.
- Where is Cyprumed located and what are their partnership experiences?
- Cyprumed is based in Innsbruck, Austria, with operations also noted in Obsteig. They entered a major license agreement with MSD (Merck & Co.) in April 2025, potentially worth up to $493 million in milestones for oral peptide development.